Allogene Therapeutics Inc
ALLO
ISIN null / Valor 43756548
Allogene Therapeutics Inc
UMushroom community rating:
About company
Allogene Therapeutics Inc is a clinical-stage biotechnology firm focused on the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer treatment. The company operates at the forefront of cell therapy research, leveraging a comprehensive, in-house team for the discovery, translational research, development, and manufacturing of cell therapies. Allogene has established significant partnerships to enhance its technological capabilities and product pipeline. This includes a collaboration with Antion for miRNA technology to improve immune evasion strategies for AlloCAR T™ candidates, granting Allogene exclusive commercialization rights for certain targets. Additionally, the company has an exclusive agreement with Notch Therapeutics to develop induced pluripotent stem cell (iPSC) AlloCAR™ products for various cancers, utilizing Notch’s Engineered Thymic Niche (ETN) platform. Allogene is also co-developing ALLO-501 and ALLO-501A, anti-CD19 therapies, in partnership with Servier, based on a license from Cellectis, with exclusive rights in the U.S. and an option for global rights. These strategic collaborations underscore Allogene's commitment to advancing its portfolio of cancer therapies through innovative research and development initiatives.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (18.10.2025):
Allogene Therapeutics Inc reported its financial results for the second quarter of 2025, demonstrating a net loss of $50.9 million and maintaining a robust cash position of $302.6 million, which is projected to sustain operations into the second half of 2027.
Research and Development Expenses
R&D expenses totaled $40.2 million for Q2 2025, including $2.6 million in non-cash stock-based compensation.
General and Administrative Expenses
General and administrative expenses were $14.3 million for the second quarter of 2025, which includes $6.1 million of non-cash stock-based compensation.
Net Loss
The net loss for Q2 2025 was $50.9 million, or $0.23 per share, which includes non-cash expenses of $8.7 million in stock-based compensation and $2.4 million in impairment of long-lived assets.
Cash Position and Runway
Allogene ended Q2 2025 with $302.6 million in cash, cash equivalents, and investments, with the cash runway projected into the second half of 2027.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
273 M
Market cap (USD)
2,369,849
Daily traded volume (Shares)
2.17 / 1.995
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
C X
C X
C X
EQUITIES OF THE SAME SECTOR
